Sign in to view content

Baseline Characteristics of Patients Who Did or Did Not Maintain 12-Week and 16-Week Aflibercept 8 mg Dosing Intervals in the Phase 2/3 PHOTON Trial

Eric W Schneider, MD

Video
Published 2023

Related

Intraocular lens luxated to the vitreous cavity
Mariam Cernichiaro-Espinosa, MD
Retina Image Bank: Images of the Week
2023
Clinical Trial Versus Real-World Outcomes With Anti-VEGF Therapy for Branch and Central Retinal Vein Occlusion
Carl J Danzig, MD
Annual Meeting Talks
2021
Advances in Diabetic Vitrectomy
Judy E. Kim, MD, FASRS
Updates from the Field
2016

Category: Diabetic Retinopathy

See more